Practical guidance for nonoccupational postexposure prophylaxis to prevent HIV infection: An editorial review

AIDS

Volumn 28, Issue 11, 2014, Pages 1545-1554

  Jain, Sachin ^a,b   Mayer, Kenneth H ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b FENWAY INSTITUTE   (United States)

Author keywords

Biomedical HIV prevention; Nonoccupational postexposure prophylaxis; NPEP; Postexposure prophylaxis

Indexed keywords

COUNSELING; DRUG INTERACTION; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; NONOCCUPATIONAL POST EXPOSURE PROPHYLAXIS; POST EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; DIAGNOSTIC PROCEDURE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; PROCEDURES; UNITED STATES; UTILIZATION;

ANTIRETROVIRUS AGENT;

ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CLINICAL LABORATORY TECHNIQUES; HIV INFECTIONS; HUMANS; POST-EXPOSURE PROPHYLAXIS; UNITED STATES;

EID: 84904728246     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000301     Document Type: Review

References (78)

1. Tsai CC, Follis KE, Sabo A, Beck TW, Grant RF, Bischofberger N, et al. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl) adenine. Science 1995; 270: 1197-1199.
2. Cardo DM, Culver DH, Ciesielski CA, Srivastava PU, Marcus R, Abiteboul D, et al. A case-control study of HIV seroconversion in healthcare workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group. N Engl J Med 1997; 337: 1485-1490.
3. Centers for Disease Control and Prevention (CDC). Public Health Service Guidelines for the Management of Health-Care Worker Exposures to HIV and Recommendations for Postexposure Prophylaxis. MMWR Recomm Rep 1998; 47: 1-33.
4. Feldhaus KM, Houry D, Kaminsky R. Lifetime sexual assault prevalence rates and reporting practices in an emergency department population. Ann Emerg Med 2000; 36: 23-27.
5. Kim JC, Martin LJ, Denny L. Rape and HIV postexposure prophylaxis: addressing the dual epidemics in South Africa. Reprod Health Matters 2003; 11: 101-112.
6. Meel BL. HIV/AIDS postexposure prophylaxis (PEP) for victims of sexual assault in South Africa. Med Sci Law 2005; 45: 219-224.
7. Linden JA. Clinical practice. Care of the adult patient after sexual assault. N Engl J Med 2011; 365: 834-841.
8. Ende AR, Hein L, Sottolano DL, Agins BD. Nonoccupational postexposure prophylaxis for exposure to HIV in New York State emergency departments. AIDS Patient Care STDS 2008; 22: 797-802.
9. Laporte A, Jourdan N, Bouvet E, Lamontagne F, Pillonel J, Desenclos JC. Postexposure prophylaxis after nonoccupational HIV exposure: impact of recommendations on physicians' experiences and attitudes. AIDS 2002; 16: 397-405.
10. Giele CM, Maw R, Carne CA. Evans BG; British Co-operative Clinical Group of the Medical Society for the Study of Venereal Diseases. Postexposure prophylaxis for nonoccupational exposure to HIV: current clinical practice and opinions in the UK. Sex Transm Infect 2002; 78: 130-132.
11. Poynten IM, Jin F, Mao L, Prestage GP, Kippax SC, Kaldor JM, et al. Nonoccupational postexposure prophylaxis, subsequent risk behaviour and HIV incidence in a cohort of Australian homosexual men. AIDS 2009; 23: 1119-1126.
12. Lunding S, Katzenstein TL, Kronborg G, Lindberg JA, Jensen J, Nielsen HI, et al. The Danish PEP registry: experience with the use of postexposure prophylaxis (PEP) following sexual exposure to HIV from 1998 to 2006. Sex Transm Dis 2010; 37: 49-52.
13. Tsai CC, Emau P, Follis KE, Beck TW, Benveniste RE, Bischofberger N, et al. Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment. J Virol 1998; 72: 4265-4273.
14. Otten RA, Smith DK, Adams DR, Pullium JK, Jackson E, Kim CN, et al. Efficacy of postexposure prophylaxis after intravaginal exposure of pig-Tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2). J Virol 2000; 74: 9771-9775.
15. Van Rompay KK, McChesney MB, Aguirre NL, Schmidt KA, Bischofberger N, Marthas ML. Two low doses of tenofovir protect newborn macaques against oral simian immunodeficiency virus infections. J Infect Dis 2001; 184: 429-438.
16. Subbarao S, Otten RA, Ramos A, Kim C, Jackson E, Monsour M, et al. Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges. J Infect Dis 2006; 194: 904-911.
17. Bourry O, Brochard P, Souquiere S, Makuwa M, Calvo J, Dereudre-Bosquet N, et al. Prevention of vaginal simian immunodeficiency virus transmission in macaques by postexposure prophylaxis with zidovudine, lamivudine and indinavir. AIDS 2009; 23: 447-454.
18. Wade NA, Birkhead GS, Warren BL, Charbonneau TT, French PT, Wang L, et al. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med 1998; 339: 1409-1414.
19. Schechter M, do Lago RF, Mendelsohn AB, Moreira RI, Moulton LH, Harrison LH, et al. Behavioral impact, acceptability, and HIV incidence among homosexual men with access to postexposure chemoprophylaxis for HIV. J Acquir Immune Defic Syndr 2004; 35: 519-525.
20. Roland ME, Neilands TB, Krone MR, Katz MH, Franses K, Grant RM, et al. Seroconversion following nonoccupational postexposure prophylaxis against HIV. Clin Infect Dis 2005; 41: 1507-1513.
21. Smith DK, Grohskopf LA, Black RJ. US Department of Health and Human Services. Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the US Department of Health and Human Services. MMWR Recomm Rep 2005; 54: 1-19.
22. Kuhar DT, Henderson DK, Struble KA, Heneine W, Thomas V, Cheever LW, et al. Updated US Public Health Service Guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis. Infect Control Hosp Epidemiol 2013; 34: 875-892.
23. New York State Department of Health AIDS Institute. Update: HIV prophylaxis following non-occupational exposure. 2013. http://www.hivguidelines. org/clinical-guidelines/postexposureprophylaxis/hiv-prophylaxis-following- nonoccupational-expo sure/. [Accessed 22 July 2013]
24. Quirino T, Niero F, Ricci E, Pusterla L, Carradori S, Gabbuti A, et al. HAART tolerability: postexposure prophylaxis in healthcare workers versus treatment in HIV-infected patients. Antivir Ther 2000; 5: 195-197.
25. Bassett IV, Freedberg KA, Walensky RP. Two drugs or threë Balancing efficacy, toxicity, and resistance in postexposure prophylaxis for occupational exposure to HIV. Clin Infect Dis 2004; 39: 395-401.
26. Pinkerton SD, Martin JN, Roland ME, Katz MH, Coates TJ, Kahn JO. Cost-effectiveness of postexposure prophylaxis after sexual or injection-drug exposure to human immunodeficiency virus. Arch Intern Med 2004; 164: 46-54.
27. Pinkerton SD, Martin JN, Roland ME, Katz MH, Coates TJ, Kahn JO. Cost-effectiveness of HIV postexposure prophylaxis following sexual or injection drug exposure in 96 metropolitan areas in the United States. AIDS 2004; 18: 2065-2073.
28. Guinot D, Ho MT, Poynten IM, McAllister J, Pierce A, Pell C, et al. Cost-effectiveness of HIV nonoccupational postexposure prophylaxis in Australia. HIV Med 2009; 10: 199-208.
29. Lee LM, Henderson DK. Tolerability of postexposure antiretroviral prophylaxis for occupational exposures to HIV. Drug Saf 2001; 24: 587-597.
30. Rabaud C, Burty C, Grandidier M, Christian B, Penalba C, Béguinot I, et al. Tolerability of postexposure prophylaxis with the combination of zidovudine-lamivudine and lopinavir-ritonavir for HIV infection. Clin Infect Dis 2005; 40: 303-305.
31. Burty C, Pavel S, Ghomari K, Vermersch A, Christian B, Pouaha J, et al. Tolerability of fosamprenavir/ritonavir associated with zidovudine-lamivudine used as postexposure prophylaxis for HIV infection. J Acquir Immune Defic Syndr 2008; 49: 334-336.
32. Pavel S, Burty C, Alcaraz I, de la Tribonnière X, Baclet V, Ajana F, et al. Severe liver toxicity in postexposure prophylaxis for HIV infection with a zidovudine, lamivudine and fosamprenavir/ritonavir regimen. AIDS 2007; 21: 268-269.
33. Diaz-Brito V, León A, Knobel H, Peraire J, Domingo P, Clotet B, et al. Postexposure prophylaxis for HIV infection: a clinical trial comparing lopinavir/ritonavir versus atazanavir each with zidovudine/lamivudine. Antivir Ther 2012; 17: 337-346.
34. Mayer KH, Mimiaga MJ, Cohen D, Grasso C, Bill R, Van Derwarker R, et al. Tenofovir DF plus lamivudine or emtricitabine for nonoccupational postexposure prophylaxis (NPEP) in a Boston Community Health Center. J Acquir Immune Defic Syndr 2008; 47: 494-499.
35. Tosini W, Muller P, Prazuck T, Benabdelmoumen G, Peyrouse E, Christian B, et al. Tolerability of HIV postexposure prophylaxis with tenofovir/ emtricitabine and lopinavir/ritonavir tablet formulation. AIDS 2010; 24: 2375-2380.
36. Burty C, Prazuck T, Truchetet F, Christian B, Penalba C, Salmon-Ceron D, et al. Tolerability of two different combinations of antiretroviral drugs including tenofovir used in occupational and nonoccupational postexposure prophylaxis for HIV. AIDS Patient Care STDS 2010; 24: 1-3.
37. Mayer KH, Mimiaga MJ, Gelman M, Grasso C. Raltegravir, tenofovir DF, and emtricitabine for postexposure prophylaxis to prevent the sexual transmission of HIV: safety, tolerability, and adherence. J Acquir Immune Defic Syndr 2012; 59: 354-359.
38. Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347: 385-394.
39. Kuritzkes DR, Lalama CM, Ribaudo HJ, Marcial M, Meyer WA 3rd, Shikuma C, et al. Preexisting resistance to nonnucleoside reverse-Transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. J Infect Dis 2008; 197: 867-870.
40. Paredes R, Lalama CM, Ribaudo HJ, Schackman BR, Shikuma C, Giguel F, et al. Preexisting minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. J Infect Dis 2010; 201: 662-671.
41. Centers for Disease Control and Prevention (CDC). Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures: worldwide, 1997-2000. Morb Mortal Wkly Rep 2001; 49: 1153-1156.
42. Bannaga A, Rahama O, Barlow G. Nevirapine-induced Stevens-Johnson syndrome following HIV postexposure prophylaxis. BMJ Case Reports 2013: published online 25 April 2013, doi: 10.1136/bcr-2013-009453.
43. Brumme ZL, Goodrich J, Mayer HB, Brumme CJ, Henrick BM, Wynhoven B, et al. Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviralnaive individuals. J Infect Dis 2005; 192: 466-474.
44. HIV Prevention Trials Network. HPTN 069: Phase II randomized, double-blind, study of safety and tolerability of maraviroc, maraviroc emtricitabine, maraviroc tenofovir or tenofovir emtricitabine for preexposure prophylaxis to prevent HIV transmission in at-risk men who have sex with men and in at-risk women. http://www.hptn.org/research-studies/hptn069.asp. [Accessed 27 February 2014]
45. Laprise C, Baril JG, Dufresne S, Trottier H. Atazanavir and other determinants of hyperbilirubinemia in a cohort of 1150 HIVpositive patients: results from 9 years of follow-up. AIDS Patient Care STDS 2013; 27: 378-386.
46. Abbas UL, Hood G, Wetzel AW, Mellors JW. Factors influencing the emergence and spread of HIV drug resistance arising from rollout of antiretroviral preexposure prophylaxis (PrEP). PLoS One 2011; 6: e18165.
47. Dolling D, PhillipsAN, Delpech V, Pillay D, Cane PA, CrookAM, et al. Evaluating the extent of potential resistance to preexposure prophylaxis within the UK HIV-1-infectious population of men who have sex with men. HIV Med 2012; 13: 309-314.
48. van de Vijver DA, Nichols BE, Abbas UL, Boucher CA, Cambiano V, Eaton JW, et al. Preexposure prophylaxis will have a limited impact on HIV-1 drug resistance in sub-Saharan Africa: a comparison of mathematical models. AIDS 2013; 27: 2943-2951.
49. Karmon SL, Markowitz M. Next-generation integrase inhibitors: where to after raltegravir? Drugs 2013; 73: 213-228.
50. Rizk ML, Hang Y, Luo WL, Su J, Zhao J, Campbell H, et al. Pharmacokinetics and pharmacodynamics of once-daily versus twice-daily raltegravir in treatment-naive HIV-infected patients. Antimicrob Agents Chemother 2012; 56: 3101-3106.
51. Clotet B, Bellos N, Molina JM, Cooper D, Goffard JC, Lazzarin A, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007; 369: 1169-1178.
52. Lefebvre E, Schiffer CA. Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir. AIDS Rev 2008; 10: 131-142.
53. Wang Y, Liu Z, Brunzelle JS, Kovari IA, Dewdney TG, Reiter SJ, et al. The higher barrier of darunavir and tipranavir resistance for HIV-1 protease. Biochem Biophys Res Commun 2011; 412: 737-742.
54. Else LJ, Taylor S, Back DJ, Khoo SH. Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract. Antivir Ther 2011; 16: 1149-1167.
55. Taylor S, Jayasuriya AN, Berry A, Gilleran G, Dufty NE, Else L, et al. Darunavir concentrations exceed the protein-corrected EC50 for wild-Type HIV in the semen of HIV-1-infected men. AIDS 2010; 24: 2583-2587.
56. Lambert-Niclot S, Peytavin G, Duvivier C, Poirot C, Algarte-Genin M, Pakianather S, et al. Low frequency of intermittent HIV-1 semen excretion in patients treated with darunavirritonavir at 600/100 milligrams twice a day plus two nucleoside reverse transcriptase inhibitors or monotherapy. Antimicrob Agents Chemother 2010; 54: 4910-4913.
57. Huang W, Frantzell A, Fransen S, Petropoulos CJ. Multiple genetic pathways involving amino acid position 143 of HIV-1 integrase are preferentially associated with specific secondary amino acid substitutions and confer resistance to raltegravir and cross-resistance to elvitegravir. Antimicrob Agents Chemother 2013; 57: 4105-4113.
58. Hightower KE, Wang R, Deanda F, Johns BA, Weaver K, Shen Y, et al. Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir fromwild-Type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes. Antimicrob Agents Chemother 2011; 55: 4552-4559.
59. Kobayashi M, Yoshinaga T, Seki T, Wakasa-Morimoto C, Brown KW, Ferris R, et al. In vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother 2011; 55: 813-821.
60. Ulirsch JC, Ballina LE, Soward AC, Rossi C, Hauda W, Holbrook D, et al. Pain and somatic symptoms are sequelae of sexual assault: results of a prospective longitudinal study. Eur J Pain 2014; 18: 559-566.
61. Green CR, Flowe-Valencia H, Rosenblum L, Tait AR. Do physical and sexual abuse differentially affect chronic pain states in women J Pain Symptom Manage 1999; 18: 420-426.
62. Stein MB, Lang AJ, Laffaye C, Satz LE, Lenox RJ, Dresselhaus TR. Relationship of sexual assault history to somatic symptoms and health anxiety in women. Gen Hosp Psychiatry 2004; 26: 178-183.
63. AIDSinfo Drug Database. Ritonavir: drug interactions. 2013. http://aidsinfo.nih.gov/drugs/244/ritonavir/33/professional#-Section-7. [Accessed 14 November 2013]
64. Delaney KP, Branson BM, Uniyal A, Phillips S, Candal D, Owen SM, et al. Evaluation of the performance characteristics of 6 rapid HIV antibody tests. Clin Infect Dis 2011; 52: 257-263.
65. Louie B, Wong E, Klausner JD, Liska S, Hecht F, Dowling T, et al. Assessment of rapid tests for detection of human immunodeficiency virus-specific antibodies in recently infected individuals. J Clin Microbiol 2008; 46: 1494-1497.
66. Owen SM, Yang C, Spira T, Ou CY, Pau CP, Parekh BS, et al. Alternative algorithms for human immunodeficiency virus infection diagnosis using tests that are licensed in the United States. J Clin Microbiol 2008; 46: 1588-1595.
67. Patel P, Bennett B, Sullivan T, Parker MM, Heffelfinger JD, Sullivan PS, et al. Rapid HIV screening: missed opportunities for HIV diagnosis and prevention. J Clin Virol 2012; 54: 42-47.
68. Centers for Disease Control and Prevention (CDC). Detection of acute HIV infection in two evaluations of a new HIV diagnostic testing algorithm: United States, 2011-2013. MMWR Morb Mortal Wkly Rep 2013; 62: 489-494.
69. Golub SA, Rosenthal L, Cohen DE, Mayer KH. Determinants of high-risk sexual behavior during postexposure prophylaxis to prevent HIV infection. AIDS Behav 2008; 12: 852-859.
70. Martin JN, Roland ME, Neilands TB, Krone MR, Bamberger JD, Kohn RP, et al. Use of postexposure prophylaxis against HIV infection following sexual exposure does not lead to increases in high-risk behavior. AIDS 2004; 18: 787-792.
71. Sonder GJ, van den Hoek A, Regez RM, Brinkman K, Prins JM, Mulder JW, et al. Trends in HIV postexposure prophylaxis prescription and compliance after sexual exposure in Amsterdam 2000-2004. Sex Transm Dis 2007; 34: 288-293.
72. Armishaw J, Hoy JF, Watson KM, Wright EJ, Price BG, Pierce AB. Nonoccupational postexposure prophylaxis in Victoria, Australia: responding to high rates of re-presentation and low rates of follow-up. Int J STD AIDS 2011; 22: 714-718.
73. Minas B, Laing S, Jordan H, Mak DB. Improved awareness and appropriate use of nonoccupational postexposure prophylaxis (nPEP) for HIV prevention following a multimodal communication strategy. BMC Public Health 2012; 12: 906.
74. Centers for Disease Control and Prevention. Incorporating HIV prevention into the medical care of persons living with HIV: recommendations of CDC, the Health Resources and Services Administration, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR 2003; 52: 1-24.
75. U.S. Department of Health and Human Services, Health Resources and Services Administration, HIV/AIDS Bureau. Guide for HIV/AIDS clinical care. Sections on Patient Education and Preventing HIV Transmission/Prevention with Positives. 2011. http://hab.hrsa.gov/deliverhivaidscare/clinicalguide11/. [Accessed 4 April 2014]
76. CDC. Compendium of evidence-based HIV behavioral interventions. http://www.cdc.gov/hiv/prevention/research/compen dium/rr/complete.html. [Accessed 4 April 2014]
77. Gilead. Truvada for PrEP medication assistance program. http://www.gilead.com/responsibility/us-patient-Access/truvada% 20for%20prep%20medication%20assistance%20program. [Accessed 4 April 2014]
78. CDC. HIV surveillance report, 2010; vol. 22. 2012. http://www.cdc.gov/ hiv/library/reports/surveillance/2011/surveillance-Report-vol-23.html. [Accessed 25 February 2014]